Intrapleural Photodynamic Therapy by Video-Assisted Thoracoscopy Followed by Anti-PD-1 NIVOLUMAB in Patients With Malignant Pleural Mesothelioma - a Pilot Study
Latest Information Update: 30 Sep 2024
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary) ; Aminolevulinic acid
- Indications Malignant-mesothelioma
- Focus Adverse reactions
- Acronyms IMPALA
- 17 May 2022 Planned End Date changed from 1 Apr 2026 to 1 May 2026.
- 17 May 2022 Planned primary completion date changed from 1 Apr 2026 to 1 May 2026.
- 14 Mar 2022 Planned End Date changed from 1 Sep 2025 to 1 Apr 2026.